Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence
Top Cited Papers
- 20 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cardiology
- Vol. 17 (9), 585-607
- https://doi.org/10.1038/s41569-020-0339-2
Abstract
The pathogenesis and clinical features of diabetic cardiomyopathy have been well-studied in the past decade, but effective approaches to prevent and treat this disease are limited. Diabetic cardiomyopathy occurs as a result of the dysregulated glucose and lipid metabolism associated with diabetes mellitus, which leads to increased oxidative stress and the activation of multiple inflammatory pathways that mediate cellular and extracellular injury, pathological cardiac remodelling, and diastolic and systolic dysfunction. Preclinical studies in animal models of diabetes have identified multiple intracellular pathways involved in the pathogenesis of diabetic cardiomyopathy and potential cardioprotective strategies to prevent and treat the disease, including antifibrotic agents, anti-inflammatory agents and antioxidants. Some of these interventions have been tested in clinical trials and have shown favourable initial results. In this Review, we discuss the mechanisms underlying the development of diabetic cardiomyopathy and heart failure in type 1 and type 2 diabetes mellitus, and we summarize the evidence from preclinical and clinical studies that might provide guidance for the development of targeted strategies. We also highlight some of the novel pharmacological therapeutic strategies for the treatment and prevention of diabetic cardiomyopathy.Keywords
This publication has 335 references indexed in Scilit:
- Relaxin Prevents Cardiac Fibroblast-Myofibroblast Transition via Notch-1-Mediated Inhibition of TGF-β/Smad3 SignalingPLOS ONE, 2013
- Myocardial dysfunction and chronic heart failure in patients with long-lasting type 1 diabetes: a 7-year prospective cohort studyActa Diabetologica, 2013
- Glucagon-Like Peptide-1 Analog Liraglutide Protects against Diabetic Cardiomyopathy by the Inhibition of the Endoplasmic Reticulum Stress PathwayJournal of Diabetes Research, 2013
- Superoxide Dismutases: Role in Redox Signaling, Vascular Function, and DiseasesAntioxidants and Redox Signaling, 2011
- Mitochondrial dysfunction in diabetic cardiomyopathyBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2011
- Identification of lipopolysaccharide‐binding peptide regions within HMGB1 and their effects on subclinical endotoxemia in a mouse modelEuropean Journal of Immunology, 2011
- Cardiac 12/15 lipoxygenase–induced inflammation is involved in heart failureThe Journal of Experimental Medicine, 2009
- Inducible and cardiac specific PTEN inactivation protects ischemia/reperfusion injuryJournal of Molecular and Cellular Cardiology, 2009
- Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stressCardiovascular Research, 2008
- Cardiac contractile dysfunction in insulin-resistant rats fed a high-fat diet is associated with elevated CD36-mediated fatty acid uptake and esterificationDiabetologia, 2007